Hologic, Inc. (NASDAQ:HOLX) has received a consensus recommendation of “Hold” from the twenty ratings firms that are currently covering the firm, MarketBeat.com reports. Eleven research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $44.63.
HOLX has been the subject of several research reports. BidaskClub downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Thursday, August 9th. Needham & Company LLC restated a “buy” rating and set a $48.00 price objective on shares of Hologic in a research report on Monday, August 13th. Canaccord Genuity cut their price objective on Hologic from $42.00 to $41.00 and set a “hold” rating for the company in a research report on Tuesday, August 14th. Deutsche Bank cut their price objective on Hologic from $45.00 to $43.00 and set a “hold” rating for the company in a research report on Monday, August 20th. Finally, Barclays downgraded Hologic from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $50.00 to $43.00 in a research report on Wednesday, September 5th. They noted that the move was a valuation call.
In other Hologic news, Director Sally Crawford sold 13,257 shares of Hologic stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $39.54, for a total value of $524,181.78. Following the completion of the sale, the director now directly owns 167,701 shares of the company’s stock, valued at approximately $6,630,897.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin Jordan Cohn sold 10,000 shares of Hologic stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $44.49, for a total transaction of $444,900.00. The disclosure for this sale can be found here. Insiders sold a total of 79,276 shares of company stock valued at $3,311,802 over the last ninety days. 0.79% of the stock is owned by corporate insiders.
Shares of Hologic stock opened at $43.25 on Friday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.95. Hologic has a 1 year low of $35.10 and a 1 year high of $45.17. The company has a market cap of $12.70 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.03 and a beta of 0.69.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). Hologic had a positive return on equity of 23.52% and a negative net margin of 3.46%. The company had revenue of $813.50 million for the quarter, compared to analyst estimates of $808.63 million. During the same quarter in the prior year, the firm earned $0.50 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. On average, analysts forecast that Hologic will post 2.4 EPS for the current fiscal year.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.